AI De Novo Protein Drug Design Platform ProteinForge Unveiled: Designing Therapeutic Proteins That Don't Exist in Nature From Scratch

AI De Novo Protein Drug Design Platform ProteinForge Unveiled: Designing Therapeutic Proteins That Don't Exist in Nature From Scratch

On July 11, 2030, Nobel Chemistry laureate David Baker's laboratory and Microsoft Research jointly released the ProteinForge protein drug design platform. For the first time, the platform achieves the complete de novo design of therapeutic proteins that do not exist in nature — not modifying existing proteins, but creating entirely new protein structures "from thin air" based on target functions.

ProteinForge's technical core is "function-driven inverse design" — users first define the desired protein function (for example, "specifically bind PD-L1 protein and block its interaction with PD-1"), and the system then generates all possible three-dimensional protein structures satisfying that functional constraint, using molecular dynamics simulations to evaluate each structure's stability, solubility, and immunogenicity.

In a demonstration, ProteinForge designed a completely novel anti-PD-L1 nanobody in just 4 hours, with binding affinity 3.7 times higher than that of similar marketed drugs. More critically, the nanobody's sequence shares less than 15% similarity with any known natural protein, meaning it is unlikely to trigger pre-existing immune responses.

"Traditional drug discovery is finding a needle in a haystack — screening from molecules that already exist in nature," said Baker. "ProteinForge draws the needle you want, then manufactures it directly."

The first three protein drugs designed by ProteinForge have entered preclinical research: a degrader targeting KRAS mutations (for pancreatic cancer treatment), a universal influenza virus neutralizing antibody, and a neurotrophic factor capable of crossing the blood-brain barrier.

The platform's cloud version is free for academic institutions, while corporate users pay an annual fee of $250,000. Fourteen pharmaceutical companies have registered to use it.

However, entirely novel proteins may carry unknown long-term safety risks — they have never existed in nature, and the body's long-term response to them is unpredictable. The FDA has required additional long-term toxicity assessments for drugs designed by ProteinForge.